HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated?

AuthorsRobert P Finger, Robyn H Guymer
JournalThe Medical journal of Australia (Med J Aust) Vol. 198 Issue 5 Pg. 260-1 (Mar 18 2013) ISSN: 1326-5377 [Electronic] Australia
PMID23496400 (Publication Type: Comparative Study, Letter)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factors
  • Ranibizumab
Topics
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Australia
  • Blindness (prevention & control)
  • Databases, Factual
  • Female
  • Health Services Accessibility (statistics & numerical data, trends)
  • Humans
  • Macular Degeneration (diagnosis, drug therapy)
  • Male
  • Outcome Assessment, Health Care
  • Ranibizumab
  • Risk Assessment
  • Severity of Illness Index
  • Vascular Endothelial Growth Factors (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: